- Home
- KNSA vs CNS Comparison
KNSA vs CNS Comparison
Compare KNSA & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | CNS |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | KNSA | CNS |
|---|---|---|
| Price | $45.36 | $63.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | $55.29 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 599.1K | 250.9K |
| Earning Date | 05-18-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 4.29% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | 0.75 | ★ 2.97 |
| Revenue | ★ $677,564,000.00 | $427,536,000.00 |
| Revenue This Year | $38.01 | $7.83 |
| Revenue Next Year | $17.42 | $11.02 |
| P/E Ratio | $61.55 | ★ $20.97 |
| Revenue Growth | ★ 60.09 | 4.07 |
| 52 Week Low | $18.26 | $58.39 |
| 52 Week High | $49.12 | $82.24 |
Technical Indicators
Market Signals| Indicator | KNSA | CNS |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 43.60 |
| Support Level | $40.47 | $63.76 |
| Resistance Level | $46.48 | $64.43 |
| Average True Range (ATR) | 2.12 | 2.10 |
| MACD | -0.09 | -0.47 |
| Stochastic Oscillator | 66.72 | 35.47 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.